VRBPAC meeting: 3 Big Pharma’s discuss their Vaccine Platforms

On January 26, 2023 the FDA’s advisory committee, VRBPAC, held their 178th meeting to Discuss Future Vaccination Regimens Addressing COVID-19.   Discussions included next generation vaccines such as mucosal, plus Moderna, Pfizer/BioNTech and Novavax got to speak about their Vaccine Platforms, updating the genetic code.

With the FDA accepting these vaccine platforms all they need to do in the future is “assess” the “varient” for whatever virus they choose to target with the vaccine!

The emergency use of COVID-19 vaccines during the pandemic has allowed, in record time, Big Pharma companies to establish their new technology vaccine platforms into the market, Platforms that can encode for whatever virus variant they choose!

What are the chances of 3 independent companies, introducing brand new technology products, all successfully gaining regulatory approval at the same time, in a record timeframe?  Now every emerging and existing disease can have a vaccine solution – just as Gates [1, 2], Fauci [2], Daszak et al wanted. [4, 5]